Cargando…

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster

Detalles Bibliográficos
Autores principales:	Wang, Qian, Bowen, Anthony, Tam, Anthony R, Valdez, Riccardo, Stoneman, Emily, Mellis, Ian A, Gordon, Aubree, Liu, Lihong, Ho, David D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058662/ https://www.ncbi.nlm.nih.gov/pubmed/37003292 http://dx.doi.org/10.1016/S1473-3099(23)00181-0

Ejemplares similares

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine
por: Wang, Qian, et al.
Publicado: (2023)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster
por: Jabagi, Marie-Joelle, et al.
Publicado: (2023)

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis
por: Huth, Luca, et al.
Publicado: (2023)

Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults
por: Vanshylla, Kanika, et al.
Publicado: (2022)

Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor
por: Hultqvist, Greta, et al.
Publicado: (2017)

Three-dose vaccination elicits neutralising antibodies against omicron
por: Wu, Mary, et al.
Publicado: (2022)

Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022)

Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease
por: Liu, D., et al.
Publicado: (2019)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

In Vitro Neutralisation of Rotavirus Infection by Two Broadly Specific Recombinant Monovalent Llama-Derived Antibody Fragments
por: Aladin, Farah, et al.
Publicado: (2012)

Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
por: Davis-Gardner, Meredith E., et al.
Publicado: (2022)

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
por: Carr, Edward J, et al.
Publicado: (2021)

Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
por: Carr, Edward J, et al.
Publicado: (2022)

Ongoing sporadic monkeypox cases: neutralising antibody detection in asymptomatic individuals
por: Moschese, Davide, et al.
Publicado: (2023)

Potent Dengue Virus Neutralization by a Therapeutic Antibody with Low Monovalent Affinity Requires Bivalent Engagement
por: Edeling, Melissa A., et al.
Publicado: (2014)

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
por: Fendler, Annika, et al.
Publicado: (2022)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023
por: Kim, Ryu Kyung, et al.
Publicado: (2023)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster
por: Wagenhäuser, Isabell, et al.
Publicado: (2023)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
por: Sheward, Daniel J, et al.
Publicado: (2022)

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
por: Wall, Emma C, et al.
Publicado: (2021)

Finite neutralisation breadth of omicron after repeated vaccination
por: Zhu, Yufang, et al.
Publicado: (2022)

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice
por: Zhang, Rong, et al.
Publicado: (2022)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes
por: Corazza, Alessandra, et al.
Publicado: (2019)

Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2
por: Resch, Matthew D., et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial
por: Branche, Angela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mm3jr7q9unk81imir03hh474au